Recombinant human hepatocyte growth factor promotes functional recovery after spinal cord injury

Kazuya Kitamura, Akio Iwanami, Kanehiro Fujiyoshi, Jun Ichi Yamane, Keigo Hikishima, Hiroshi Funakoshi, Toshikazu Nakamura, Masashi Aoki, Yoshiaki Toyama, Hideyuki Okano, Masaya Nakamura

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Hepatocyte growth factor (HGF), which is a potent mitogen for mature hepatocytes and a mediator of the inflammatory responses to tissue injury, was recently highlighted as a potent neurotrophic factor in the central nervous system. We revealed that introducing exogenous HGF into the injured rat spinal cord using a herpes simplex virus-1 vector significantly reduces the area of damaged tissue and promotes functional recovery. However, this rat study did not examine the therapeutic effects of administering HGF after injury, which is the most critical issue for clinical application. To translate this strategy to human treatment, we induced a contusive cervical SCI in the common marmoset, a primate, and then administered recombinant human HGF (rhHGF) intrathecally. Motor function was assessed using an original open-field scoring system focusing on manual function, including reach-and-grasp performance and hand placement in walking. The intrathecal rhHGF preserved the corticospinal fibers and myelinated areas, thereby promoting functional recovery. This study demonstrates the therapeutic effects, safety, and clinical efficacy of intrathecal rhHGF treatment for SCI in adult nonhuman primates and the possibility that this novel therapy may be suitable for clinical application.

Original languageEnglish
Title of host publicationNeuroprotection and Regeneration of the Spinal Cord
PublisherSpringer Japan
Pages147-167
Number of pages21
Volume9784431545026
ISBN (Print)9784431545026, 4431545018, 9784431545019
DOIs
Publication statusPublished - 2013 Nov 1

Fingerprint

Hepatocyte Growth Factor
Spinal Cord Injuries
Therapeutic Uses
Primates
Callithrix
Nerve Growth Factors
Wounds and Injuries
Human Herpesvirus 1
Hand Strength
Mitogens
Walking
Hepatocytes
Spinal Cord
Central Nervous System
Hand
Safety
human HGF protein
Therapeutics

Keywords

  • Clinical application
  • Hepatocyte growth factor
  • Nonhuman primate
  • Recombinant human hepatocyte growth factor
  • Spinal cord injury

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kitamura, K., Iwanami, A., Fujiyoshi, K., Yamane, J. I., Hikishima, K., Funakoshi, H., ... Nakamura, M. (2013). Recombinant human hepatocyte growth factor promotes functional recovery after spinal cord injury. In Neuroprotection and Regeneration of the Spinal Cord (Vol. 9784431545026, pp. 147-167). Springer Japan. https://doi.org/10.1007/978-4-431-54502-6_14

Recombinant human hepatocyte growth factor promotes functional recovery after spinal cord injury. / Kitamura, Kazuya; Iwanami, Akio; Fujiyoshi, Kanehiro; Yamane, Jun Ichi; Hikishima, Keigo; Funakoshi, Hiroshi; Nakamura, Toshikazu; Aoki, Masashi; Toyama, Yoshiaki; Okano, Hideyuki; Nakamura, Masaya.

Neuroprotection and Regeneration of the Spinal Cord. Vol. 9784431545026 Springer Japan, 2013. p. 147-167.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kitamura, K, Iwanami, A, Fujiyoshi, K, Yamane, JI, Hikishima, K, Funakoshi, H, Nakamura, T, Aoki, M, Toyama, Y, Okano, H & Nakamura, M 2013, Recombinant human hepatocyte growth factor promotes functional recovery after spinal cord injury. in Neuroprotection and Regeneration of the Spinal Cord. vol. 9784431545026, Springer Japan, pp. 147-167. https://doi.org/10.1007/978-4-431-54502-6_14
Kitamura K, Iwanami A, Fujiyoshi K, Yamane JI, Hikishima K, Funakoshi H et al. Recombinant human hepatocyte growth factor promotes functional recovery after spinal cord injury. In Neuroprotection and Regeneration of the Spinal Cord. Vol. 9784431545026. Springer Japan. 2013. p. 147-167 https://doi.org/10.1007/978-4-431-54502-6_14
Kitamura, Kazuya ; Iwanami, Akio ; Fujiyoshi, Kanehiro ; Yamane, Jun Ichi ; Hikishima, Keigo ; Funakoshi, Hiroshi ; Nakamura, Toshikazu ; Aoki, Masashi ; Toyama, Yoshiaki ; Okano, Hideyuki ; Nakamura, Masaya. / Recombinant human hepatocyte growth factor promotes functional recovery after spinal cord injury. Neuroprotection and Regeneration of the Spinal Cord. Vol. 9784431545026 Springer Japan, 2013. pp. 147-167
@inbook{cc0680abbc24404e92f234000eee23cd,
title = "Recombinant human hepatocyte growth factor promotes functional recovery after spinal cord injury",
abstract = "Hepatocyte growth factor (HGF), which is a potent mitogen for mature hepatocytes and a mediator of the inflammatory responses to tissue injury, was recently highlighted as a potent neurotrophic factor in the central nervous system. We revealed that introducing exogenous HGF into the injured rat spinal cord using a herpes simplex virus-1 vector significantly reduces the area of damaged tissue and promotes functional recovery. However, this rat study did not examine the therapeutic effects of administering HGF after injury, which is the most critical issue for clinical application. To translate this strategy to human treatment, we induced a contusive cervical SCI in the common marmoset, a primate, and then administered recombinant human HGF (rhHGF) intrathecally. Motor function was assessed using an original open-field scoring system focusing on manual function, including reach-and-grasp performance and hand placement in walking. The intrathecal rhHGF preserved the corticospinal fibers and myelinated areas, thereby promoting functional recovery. This study demonstrates the therapeutic effects, safety, and clinical efficacy of intrathecal rhHGF treatment for SCI in adult nonhuman primates and the possibility that this novel therapy may be suitable for clinical application.",
keywords = "Clinical application, Hepatocyte growth factor, Nonhuman primate, Recombinant human hepatocyte growth factor, Spinal cord injury",
author = "Kazuya Kitamura and Akio Iwanami and Kanehiro Fujiyoshi and Yamane, {Jun Ichi} and Keigo Hikishima and Hiroshi Funakoshi and Toshikazu Nakamura and Masashi Aoki and Yoshiaki Toyama and Hideyuki Okano and Masaya Nakamura",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/978-4-431-54502-6_14",
language = "English",
isbn = "9784431545026",
volume = "9784431545026",
pages = "147--167",
booktitle = "Neuroprotection and Regeneration of the Spinal Cord",
publisher = "Springer Japan",

}

TY - CHAP

T1 - Recombinant human hepatocyte growth factor promotes functional recovery after spinal cord injury

AU - Kitamura, Kazuya

AU - Iwanami, Akio

AU - Fujiyoshi, Kanehiro

AU - Yamane, Jun Ichi

AU - Hikishima, Keigo

AU - Funakoshi, Hiroshi

AU - Nakamura, Toshikazu

AU - Aoki, Masashi

AU - Toyama, Yoshiaki

AU - Okano, Hideyuki

AU - Nakamura, Masaya

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Hepatocyte growth factor (HGF), which is a potent mitogen for mature hepatocytes and a mediator of the inflammatory responses to tissue injury, was recently highlighted as a potent neurotrophic factor in the central nervous system. We revealed that introducing exogenous HGF into the injured rat spinal cord using a herpes simplex virus-1 vector significantly reduces the area of damaged tissue and promotes functional recovery. However, this rat study did not examine the therapeutic effects of administering HGF after injury, which is the most critical issue for clinical application. To translate this strategy to human treatment, we induced a contusive cervical SCI in the common marmoset, a primate, and then administered recombinant human HGF (rhHGF) intrathecally. Motor function was assessed using an original open-field scoring system focusing on manual function, including reach-and-grasp performance and hand placement in walking. The intrathecal rhHGF preserved the corticospinal fibers and myelinated areas, thereby promoting functional recovery. This study demonstrates the therapeutic effects, safety, and clinical efficacy of intrathecal rhHGF treatment for SCI in adult nonhuman primates and the possibility that this novel therapy may be suitable for clinical application.

AB - Hepatocyte growth factor (HGF), which is a potent mitogen for mature hepatocytes and a mediator of the inflammatory responses to tissue injury, was recently highlighted as a potent neurotrophic factor in the central nervous system. We revealed that introducing exogenous HGF into the injured rat spinal cord using a herpes simplex virus-1 vector significantly reduces the area of damaged tissue and promotes functional recovery. However, this rat study did not examine the therapeutic effects of administering HGF after injury, which is the most critical issue for clinical application. To translate this strategy to human treatment, we induced a contusive cervical SCI in the common marmoset, a primate, and then administered recombinant human HGF (rhHGF) intrathecally. Motor function was assessed using an original open-field scoring system focusing on manual function, including reach-and-grasp performance and hand placement in walking. The intrathecal rhHGF preserved the corticospinal fibers and myelinated areas, thereby promoting functional recovery. This study demonstrates the therapeutic effects, safety, and clinical efficacy of intrathecal rhHGF treatment for SCI in adult nonhuman primates and the possibility that this novel therapy may be suitable for clinical application.

KW - Clinical application

KW - Hepatocyte growth factor

KW - Nonhuman primate

KW - Recombinant human hepatocyte growth factor

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84930710371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930710371&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-54502-6_14

DO - 10.1007/978-4-431-54502-6_14

M3 - Chapter

AN - SCOPUS:84930710371

SN - 9784431545026

SN - 4431545018

SN - 9784431545019

VL - 9784431545026

SP - 147

EP - 167

BT - Neuroprotection and Regeneration of the Spinal Cord

PB - Springer Japan

ER -